+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dengue Vaccine - Global Strategic Business Report

  • PDF Icon

    Report

  • 193 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5139682
The global market for Dengue Vaccine was estimated at US$589.0 Million in 2023 and is projected to reach US$1.6 Billion by 2030, growing at a CAGR of 15.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The dengue vaccine, also known as CYD-TDV or by its commercial name Dengvaxia, is the first vaccine approved for the prevention of dengue disease, caused by the dengue virus. Dengue is transmitted by mosquitoes and is prevalent in tropical and subtropical climates worldwide, affecting millions annually with severe flu-like symptoms and potentially life-threatening complications. The vaccine is a live recombinant tetravalent response to all four virus serotypes, utilizing a weakened version of the yellow fever virus as a vector to express dengue virus proteins. This stimulates the immune system to produce a defense mechanism specifically targeted against the dengue virus if it enters the human body. However, its use is recommended only in populations that are seropositive, meaning they have been previously infected by the virus, as the vaccine can increase the risk of severe dengue in seronegative individuals, those who have never been exposed to the virus.

What Are the Clinical Insights and Public Health Benefits of the Dengue Vaccine?

Clinical trials for the dengue vaccine have shown varied efficacy rates across different serotypes and age groups, with overall efficacy hovering around 60%. The vaccine's effectiveness is notably higher in individuals who have had a previous dengue infection, underscoring its utility in endemic regions where such exposure is common. Public health benefits of the vaccine include reduced hospitalization rates and a decrease in severe dengue cases, which are significant in helping ease the burden on healthcare systems in affected regions. The vaccine is thus considered a critical tool in the fight against dengue, particularly in high-prevalence areas. By reducing the incidence of dengue, it not only saves lives but also reduces economic loss related to healthcare costs and lost productivity due to illness.

What Are the Challenges and Considerations in the Deployment of the Dengue Vaccine?

The deployment of the dengue vaccine has faced several challenges and ethical considerations. One major issue is determining vaccine eligibility, particularly in identifying individuals previously infected by the dengue virus. This requires reliable serological testing, which can be costly and logistically challenging in resource-poor settings. There's also the risk of vaccine-related severe dengue in seronegative vaccine recipients, which has led to controversies and public distrust in some regions following early roll-outs. These challenges necessitate careful planning and public communication strategies to maximize benefits and minimize risks associated with vaccination. Additionally, ongoing research and surveillance are crucial to monitor long-term vaccine safety and effectiveness, especially as the virus evolves and different population dynamics come into play.

What Drives the Growth in the Dengue Vaccine Market?

The growth in the dengue vaccine market is driven by several factors, primarily the high burden of disease in over 100 countries, increasing the demand for effective preventive measures. The expansion of endemic areas due to global warming and increased urbanization, which create ideal breeding conditions for mosquitoes, also spur the need for vaccines. Furthermore, growing international travel continues to introduce dengue into new regions, raising global concern and demand for vaccination. Advances in vaccine technology and increased funding for dengue research have accelerated the development and improvement of dengue vaccines, making them more accessible and affordable. Public-private partnerships and initiatives by global health bodies like the World Health Organization (WHO) to promote vaccination as part of integrated dengue prevention plans also contribute to the growth of the market. These factors, combined with a heightened awareness of the impact of dengue and the availability of preventive options, ensure a dynamic and expanding market for the dengue vaccine.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Government Institutions End-Use segment, which is expected to reach US$774.6 Million by 2030 with a CAGR of a 14.2%. The Hospitals End-Use segment is also set to grow at 16.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $151.9 Million in 2023, and China, forecasted to grow at an impressive 20.1% CAGR to reach $412.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Dengue Vaccine Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Dengue Vaccine Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Dengue Vaccine Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Biological E. Ltd., GlaxoSmithKline plc, Instituto Butantan, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 44 Featured):

  • Biological E. Ltd.
  • GlaxoSmithKline plc
  • Instituto Butantan
  • Panacea Biotec Ltd.
  • Sanofi SA
  • Takeda Pharmaceuticals Company Ltd.
  • Vabiotech

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Dengue Vaccine - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Global Prevalence of Dengue Fever Drives Urgency for Vaccine Development
  • Increasing Government and NGO Funding Propels Dengue Vaccine Research and Trials
  • Expansion of Vaccine Coverage in Endemic Regions Enhances Market Opportunities
  • Growing Public Health Initiatives Support Dengue Vaccination Programs
  • Integration of Dengue Vaccination in National Immunization Programs
  • Rising Travel and Migration Patterns Increase Demand for Dengue Vaccination
  • Growing Awareness Campaigns Enhance Public Acceptance of Dengue Vaccination
  • Growing Pediatric Population in Dengue-Prevalent Regions Drives Market Demand
  • Emergence of Vaccine Tourism in Dengue Endemic Regions
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Dengue Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Government Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Government Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Government Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for NGOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 13: World Dengue Vaccine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 15: USA Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: USA 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Canada Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: Canada 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
JAPAN
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Japan Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: Japan 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
CHINA
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 24: China Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: China 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
EUROPE
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Dengue Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: Europe 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
FRANCE
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: France Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: France 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
GERMANY
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Germany Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Germany 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Italy Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Italy 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: UK Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: UK 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
SPAIN
  • TABLE 44: Spain Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Spain Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Spain 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
RUSSIA
  • TABLE 47: Russia Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Russia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Russia 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
REST OF EUROPE
  • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Rest of Europe Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Rest of Europe 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 54: Asia-Pacific Historic Review for Dengue Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Asia-Pacific 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Asia-Pacific Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: Asia-Pacific 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
AUSTRALIA
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 59: Australia Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Australia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: Australia 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
INDIA
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 62: India Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: India Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: India 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
SOUTH KOREA
  • TABLE 65: South Korea Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: South Korea Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: South Korea 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
  • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Rest of Asia-Pacific Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
LATIN AMERICA
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 71: Latin America Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 72: Latin America Historic Review for Dengue Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Latin America 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 74: Latin America Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Latin America Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: Latin America 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
ARGENTINA
  • TABLE 77: Argentina Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Argentina Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: Argentina 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
BRAZIL
  • TABLE 80: Brazil Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Brazil Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Brazil 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
MEXICO
  • TABLE 83: Mexico Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Mexico Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Mexico 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
  • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Rest of Latin America Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Rest of Latin America 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
MIDDLE EAST
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 89: Middle East Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 90: Middle East Historic Review for Dengue Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Middle East 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 92: Middle East Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Middle East Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Middle East 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
IRAN
  • TABLE 95: Iran Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Iran Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Iran 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
ISRAEL
  • TABLE 98: Israel Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Israel Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Israel 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
SAUDI ARABIA
  • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Saudi Arabia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Saudi Arabia 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
  • TABLE 104: UAE Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: UAE Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: UAE 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
  • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Rest of Middle East Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Rest of Middle East 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
AFRICA
  • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 110: Africa Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Africa Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: Africa 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Biological E. Ltd.
  • GlaxoSmithKline plc
  • Instituto Butantan
  • Panacea Biotec Ltd.
  • Sanofi SA
  • Takeda Pharmaceuticals Company Ltd.
  • Vabiotech

Table Information